GLP1-RAs Reduce Blood Clot Risk in T2DM; Zealand Initiates Ph2b Petrelintide Obesity Trial Enrollment; NewAmsterdam Positive CETPi Ph3 HeFH Data
Three cardiometabolic-related news items have been observed: GLP-1RAs reportedly demonstrated potential to decrease venous thromboembolisms (VTEs) in patients with T2DM (view article); Zealand initiated enrollment for the Ph2b ZUPREME-1 trial of petrelintide in obesity (view press release); and NewAmsterdam announced positive topline data from its Ph3 BROADWAY trial of obicetrapib in HeFH (view press release). FENIX will provide an overview of the updated ADA/EASD 2025 guidelines in tomorrow’s blast. Below, FENIX provides highlights and insights for the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.